In this podcast episode, CLINUVEL’s Regulatory Affairs Project Manager (Cosmetics), Alice Lynn joined Sarah Mawson to unpack SPF: what is it? How do we test for it? And why some labels may not be what they seem.

In this podcast episode, Dr Emilie Rodenburger, Director, Global Clinical Affairs at CLINUVEL, elaborates on the scientific basis for using afamelanotide in vitiligo, and provides insights on key learnings from the program to date.

Dr Grimes, Non-Executive Director at CLINUVEL, discusses the current treatment landscape in the field of vitiligo—including the positive progress in regulatory issues and reimbursement of treatment—as well as the future for vitiligo patients.

Dr Dennis Wright, CLINUVEL’s Chief Scientific Officer, explains the rationale behind the clinical endpoints of the Company’s CUV105 vitiligo study, as well as the program’s pathway to market.

Reduced staff over the weekends is the norm for many retail shops, but what about in healthcare? A number of reviews have...

Those of us working from offices, or our own homes, aren’t expecting danger pay.  However, what about those who have jobs that heighten the risk of getting skin...

Most of us have been spun a myth that eating our crusts will make our hair shiny, and that we should...

Quarantine fatigue amongst the general public may result in a higher incidence rate of sunburn, according to a recent analysis of...

CLINUVEL (ASX:CUV) hosted an investor webinar to review the half year results and operational highlights for the six months ended on 31 December 2024.

Guy van Dievoet was appointed Non-Executive Director in 2024, alongside Matthew Pringle and Dr Pearl Grimes. In a video in February 2025, he elaborates on the Company’s approach to creating value as a speciality pharmaceutical group and pursuing M&A opportunities.

Matthew Pringle joined CLINUVEL as a Non-Executive Director in 2024. In this video released in February 2025, Mr Pringle discusses the role of Directors, and the Company’s approach to capital management and building long-term incremental value as it works to realise its objectives.

Each January San Francisco plays host to the J.P. Morgan Healthcare Conference, the largest event of its kind.